Side-by-side · Research reference

GonadorelinvsThymosin α-1

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedHUMAN-REVIEWED7/61 cited

BPhase 3HUMAN-REVIEWED8/39 cited

Gonadorelin

GnRH Analogue · Diagnostic & Therapeutic

90 minPulsatile interval

73%Ovulation restorationTadesse 2026

2–4 minPlasma half-life

IV / SQ · Pulsatile Pump (Therapeutic) · Single Bolus (Diagnostic)

Thymosin α-1

Immune modulator · Approved (some countries)

1.6 mgPer doseIyer 2007

Phase 3Evidence levelIyer 2007 Camerini 2001

~2 hrHalf-life

SQ · 2× weekly · 6+ months for chronic indications

01Mechanism of Action

Parameter

Gonadorelin

Thymosin α-1

Primary target

GnRH receptors on anterior pituitary gonadotropes

Toll-like receptor 9 (TLR9) + T-cell maturation pathwayCamerini 2001

Pathway

GnRH → Pituitary gonadotrope → LH/FSH secretion → Gonadal steroidogenesisSharma 2026

TLR9 activation → ↑ IFN-α + IL-2 + IFN-γ → enhanced T-cell function + dendritic cell maturationIyer 2007

Downstream effect

Pulsatile LH/FSH release stimulates testicular testosterone or ovarian estradiol/progesterone synthesis; initiates folliculogenesis and spermatogenesisRobin 2026 Sharma 2026

Restored T-cell function, improved viral clearance, anti-tumour adjuvant effectsIyer 2007

Feedback intact?

Yes — pulsatile delivery preserves negative feedback loops; continuous exposure desensitizes receptors

—

Origin

Synthetic decapeptide (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2) identical to native hypothalamic GnRH

Synthetic 28-AA peptide identical to natural Tα-1 isolated from thymus extractCamerini 2001

Antibody development

—

02Dosage Protocols

Parameter

Gonadorelin

Thymosin α-1

Diagnostic test (pituitary function)

100 mcg IV or SQ bolus

Measure baseline LH/FSH, then 30/60/90 min post-injection. Normal response: LH ≥2× baseline.

—

Therapeutic (hypothalamic hypogonadism)

5–20 mcg IV bolus every 90–120 minutes

Requires portable pulsatile pump. Dose individualized to achieve normal gonadotropin pulsatility.Robin 2026

—

Pulsatile interval

90 minutes (females) · 120 minutes (males)

Mimics physiological GnRH pulse frequency.

—

Route

IV preferred (therapeutic) · SQ acceptable (diagnostic)

—

Duration

Continuous until pregnancy achieved or fertility goals met

3–6 month courses typical for ovulation induction.

6–12 months for chronic indications

Evidence basis

RCT / Expert consensus

Phase 3 + approved (35+ countries as Zadaxin)Iyer 2007

Half-life

2–4 minutes (plasma)

Necessitates frequent pulsatile administration.

~2 hours plasma; tissue effect days

Alternative protocols

Exogenous gonadotropins (hCG/hMG) often preferred due to convenience vs pump requirement

—

Standard dose (HBV/HCV)

—

1.6 mg SQ 2× weekly × 6–12 monthsIyer 2007

Frequency

—

2× weekly (Mon/Thu typical)

Lower / starter dose

—

0.8 mg per injection

Reconstitution

—

Sterile water for injection per vial label

Timing

—

No specific time

03Metabolic / Fat Loss Evidence

Parameter

Gonadorelin

Thymosin α-1

Fat loss mechanism

None — gonadorelin acts exclusively on reproductive axis

—

Indirect metabolic effects

Restoration of sex hormones may normalize body composition in hypogonadal states

Effect mediated by downstream testosterone/estradiol, not GnRH itself.

—

04Side Effects & Safety

Parameter

Gonadorelin

Thymosin α-1

Injection site reaction

Erythema, irritation (pulsatile pump catheter site)

Erythema, mild discomfort

Headache

Common with bolus administration

—

Nausea / abdominal discomfort

Transient, dose-related

—

Ovarian hyperstimulation syndrome (OHSS)

Risk with ovulation induction protocols; monitor follicular development via ultrasound

—

Multiple gestation

Increased risk with fertility protocols (twins ~10–15%)

—

Anaphylaxis

Rare hypersensitivity reaction

—

Pump malfunction / infection

Mechanical failure or catheter-site infection with long-term IV pump use

—

Receptor desensitization

Continuous (non-pulsatile) exposure paradoxically suppresses gonadotropinsRobin 2026

—

GI symptoms

—

Rare nausea

Fatigue

—

Common during initial weeks

Fever / flu-like

—

Mild interferon-like response possible

Autoimmune

—

Theoretical risk; caution in active autoimmune disease

Cancer risk

—

No signal — used as adjuvant in oncology

Pregnancy / OB

—

Avoid

Absolute Contraindications

Gonadorelin

·Pregnancy (except therapeutic infertility protocols)
·Hypersensitivity to gonadorelin or excipients
·Hormone-dependent tumors (prostate, breast) — risk of tumor stimulation via sex hormone elevation

Thymosin α-1

·Pregnancy / breastfeeding
·Hypersensitivity to peptide
·Concurrent immunosuppressant therapy (transplant patients)

Relative Contraindications

Gonadorelin

·Ovarian cysts or PCOS (monitor for OHSS)
·Pituitary adenoma or other sellar mass (may worsen with gonadotropin surge)

Thymosin α-1

·Active autoimmune disease
·Severe immunocompromised state without supervision

05Administration Protocol

Parameter

Gonadorelin

Thymosin α-1

1. Diagnostic protocol

Administer 100 mcg IV or SQ bolus. Draw baseline LH/FSH, then at 30, 60, 90 minutes. Normal response: LH ≥2× baseline, FSH modest rise. Blunted response suggests pituitary pathology; exaggerated response may indicate primary hypogonadism.

Add 1 mL sterile water per 1.6 mg vial → 1.6 mg/mL.

2. Therapeutic pump setup (pulsatile)

Requires programmable infusion pump with IV catheter. Set pulse interval to 90 min (females) or 120 min (males). Bolus dose 5–20 mcg per pulse. Pump worn continuously; catheter site rotated every 48–72 hrs to prevent infection.

SQ — abdomen, thigh, or upper arm. Rotate sites.

3. Reconstitution

Lyophilised gonadorelin reconstituted with sterile saline or provided diluent. Typically 0.8–3.2 mg dissolved in 8 mL for pump reservoir. Solution stable 7–14 days refrigerated.

2× weekly, e.g. Monday + Thursday.

4. Monitoring

For fertility protocols: ultrasound follicular tracking + serial estradiol/LH measurements. Adjust pulse dose to achieve mid-follicular LH 5–10 IU/L. Ovulation confirmed by progesterone rise or ultrasound.

Lyophilised: refrigerate. Reconstituted: refrigerate, use within 24 h.

5. Timing

Pulsatile therapy initiated at any point in cycle. Diagnostic test performed in morning (higher baseline LH). For ovulation induction, treatment begins early follicular phase.

27–31G, 4–8 mm insulin syringe.

06Stack Synergy

Gonadorelin

+ hCG (Human Chorionic Gonadotropin)

Multi-pathway

View hCG (Human Chorionic Gonadotropin) →

In hypogonadotropic hypogonadism protocols, gonadorelin restores pituitary LH/FSH pulsatility, while exogenous hCG directly stimulates Leydig cells (acting as LH mimetic) to maintain testosterone production. This dual approach ensures both central axis restoration and immediate gonadal steroidogenesis, preventing testicular atrophy during fertility treatment. hCG's longer half-life (24–36 hrs) complements gonadorelin's pulsatile short-acting profile.

Gonadorelin: 5–10 mcg IV every 120 min (pulsatile pump)
hCG: 1500–2000 IU SQ · 2–3× per week
Duration: 12–24 weeks for spermatogenesis induction
Primary benefit: Fertility restoration in hypothalamic hypogonadism with maintained testicular function

Thymosin α-1

— no documented stacks